Next Article in Journal
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
Next Article in Special Issue
A Novel Role for NUAK1 in Promoting Ovarian Cancer Metastasis through Regulation of Fibronectin Production in Spheroids
Previous Article in Journal
Conditionally Replicative Adenovirus Controlled by the Stabilization System of AU-Rich Elements Containing mRNA
Previous Article in Special Issue
The Extracellular Matrix Influences Ovarian Carcinoma Cells’ Sensitivity to Cisplatinum: A First Step towards Personalized Medicine
Review

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer

by 1,2, 3,4,5, 6,7, 4,5 and 3,4,5,*
1
Department of Hematology/Medical Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
2
Department of Hematology/Medical Oncology, Harvard Medical School, Boston, MA 02115, USA
3
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA
4
Department of Obstetrics and Gynecology, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA 02114, USA
5
Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA 02115, USA
6
Department of Pathology, Brigham and Women’s Hospital, Boston, MA 02115, USA
7
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(5), 1206; https://doi.org/10.3390/cancers12051206
Received: 8 April 2020 / Revised: 29 April 2020 / Accepted: 5 May 2020 / Published: 11 May 2020
(This article belongs to the Special Issue Preclinical and Clinical Advances in Ovarian Cancer)
High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic cancer in the United States. Genomic analysis revealed roughly half of HGSOC display homologous repair deficiencies. An improved understanding of the genomic and somatic mutations that influence DNA repair led to the development of poly(ADP-ribose) polymerase inhibitors for the treatment of ovarian cancer. In this review, we explore the preclinical and clinical studies that led to the development of FDA approved drugs that take advantage of the synthetic lethality concept, the implementation of the early phase trials, the development of companion diagnostics and proposed mechanisms of resistance. View Full-Text
Keywords: homologous repair deficiency; BRCA; ovarian cancer; PARP; resistance homologous repair deficiency; BRCA; ovarian cancer; PARP; resistance
Show Figures

Figure 1

MDPI and ACS Style

Bouberhan, S.; Philp, L.; Hill, S.; Al-Alem, L.F.; Rueda, B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers 2020, 12, 1206. https://doi.org/10.3390/cancers12051206

AMA Style

Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers. 2020; 12(5):1206. https://doi.org/10.3390/cancers12051206

Chicago/Turabian Style

Bouberhan, Sara, Lauren Philp, Sarah Hill, Linah F. Al-Alem, and Bo Rueda. 2020. "Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer" Cancers 12, no. 5: 1206. https://doi.org/10.3390/cancers12051206

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop